Compare TDOC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | MPLT |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2015 | N/A |
| Metric | TDOC | MPLT |
|---|---|---|
| Price | $6.77 | $30.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 7 |
| Target Price | $7.56 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 5.1M | 275.5K |
| Earning Date | 04-29-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | N/A |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $12.24 |
| 52 Week High | $9.77 | $33.28 |
| Indicator | TDOC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 56.58 |
| Support Level | $6.74 | $26.70 |
| Resistance Level | $7.95 | $32.68 |
| Average True Range (ATR) | 0.38 | 2.54 |
| MACD | 0.07 | -0.43 |
| Stochastic Oscillator | 72.45 | 62.04 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.